RedHill Biopharma Ltd.
Tel Aviv
- Website not added yet
- LinkedIn not added yet
- X not added yet
- Instagram not added yet
- Facebook not added yet
RedHill Biopharma Ltd was founded by Shmuel Cabilly, June D Almenoff, Ofer Tsimchi, Rick D Scruggs, Nicolas D Weinstein, Alla D Felder, Micha D Ben Chorin, Adi D Frish, Gilead D Raday, Guy D Goldberg, Eric Swenden, Dror Ben-Asher, Kenneth Reed, Reza D Fathi, Gilead Raday, Reza Fathi, Rick Scruggs, Micha Ben Chorin, Adi Frish, Guy Goldberg, Alla Felder, June Almenoff and Razi ingber, and is based in Tel Aviv.
Key facts
- Industry
- Pharmaceuticals
- Legal form
- Incorporated in L3
- Listed
- Nasdaq · RDHL
About
Pharmaceutical Preparations; listed on Nasdaq as RDHL; filing with the SEC since 2013
Founders
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer, Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer, Director
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer, Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Executive Officer
1500 Founder Rating
Executive Officer
1500 Founder Rating
In context
We hold 687 other pharmaceuticals companies. None has a closure on record yet. Of the 638 that report what they raised, the median is $4,127,748.
Counted across this directory, from founding and closing years in public records. Medians cover only companies whose closure is recorded; a company with no closure date may have quietly ceased without the record catching it.
Discussion
Log in to join the discussion and like comments.
Log In to Comment